SecBot SecBot
PRESS-RELEASE ·Filed Nov 2, 2026

BVS

Bioventus, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed14d 11h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor the strategic alternatives review for potential M&A outcomes. The revenue miss and narrowed guidance suggest near-term headwinds, but the EPS beat and strong cash flow support the current valuation. Watch for any update on the strategic review in the coming weeks.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$10.95
T+0 close · Nov 2, 2026 · via day close
Latest settled
+2.15%
T+5 · $11.18 · next T+20 in 15d
Vs SPY
+2.73%
α at T+5
Latest observation
−1.46%
T+8 · FF3 residual α
  1. T+0 · Nov 3 $10.95entry
  2. T+1 · 13d ago +4.34%α +2.69% · $11.42
  3. T+5 · 7d ago +2.15%α +2.73% · $11.18
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Bioventus reported Q3 2026 non-GAAP EPS of $0.17, beating the $0.16 consensus by 6.3%, while revenue of $142.4M missed the $149.5M consensus by 4.7%. The company reaffirmed its full-year adjusted EPS guidance of $0.75-$0.79 but narrowed net sales guidance to $590M-$595M, implying 4-5% growth. The ongoing review of strategic alternatives adds an M&A overhang.

Key Financial Metrics

EPS (Adj.)
$0.17
est $0.16 · +6.3% · GAAP: $0.08
Revenue
$142.4M
est $149.5M · -4.7% · +2.7% YoY
Rating
in line
Guidance
$590M-$595M
maintained
Gross Margin
68.2%

Key Facts

  • Non-GAAP EPS of $0.17 beat consensus of $0.16 by 6.3%
  • Revenue of $142.4M missed consensus of $149.5M by 4.7%
  • Revenue grew 2.7% YoY, below the 5% bullish threshold
  • Pain Treatments revenue grew 6.2% YoY to $71.3M
  • Restorative Therapies revenue declined 3.4% YoY to $20.6M
  • Adjusted EBITDA of $28.4M grew 7% YoY
  • Operating cash flow was $20.7M in Q3
  • Company made a $15M discretionary principal prepayment on term loan
  • Full-year adjusted EPS guidance reaffirmed at $0.75-$0.79
  • Full-year net sales guidance updated to $590M-$595M (4-5% growth)
  • Company continues to review potential strategic alternatives

Financial Impact

Non-GAAP EPS beat by $0.01 (6.3%), revenue miss of $7.1M (4.7%)

revenueepsadjusted ebitdaoperating cash flow

Segment Breakdown

SegmentRevenueGrowth
Pain Treatments$71.3M+6.2%
Surgical Solutions$50.5M+0.7%
Restorative Therapies$20.6M-3.4%

Risk Factors

  • Revenue miss of 4.7% vs consensus signals softer top-line momentum
  • Restorative Therapies segment declining 3.4% YoY
  • Strategic alternatives review creates uncertainty around future direction
  • Cash and cash equivalents declined to $30.7M from $51.2M at year-end 2025

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3393722

Track record

18 reports on BVS

Performance horizon

2 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +37.19% at T+60 after the May 8, 2026 report. 3 of 7 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $10.66 Now $10.46 −1.88% settles Feb 11
  2. Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $10.61 Now $10.46 −1.41% settles Feb 4
  3. Nov 2, 202614d ago 8-K Neutral 5/10 No price data
  4. Nov 2, 202614d ago Press Release Neutral 5/10 Viewing Entry $10.95 Now $10.46 −4.43% settles Feb 1
  5. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $14.65 Now $10.46 −28.60% settles Jan 26
  6. Aug 15, 202613w ago Institutional Cluster Mixed 5/10 Entry $13.88 to $11.02 Now $10.46 −24.64% ▼ −20.64% −17.88% vs SPY
  7. Aug 5, 202614w ago 8-K Bullish 7/10 No price data
  8. Aug 5, 202614w ago Press Release Bullish 7/10 Entry $15.26 to $14.86 Now $10.46 −31.45% ▼ −2.62% −2.81% vs SPY
  9. Jun 11, 202622w ago Institutional Cluster Bearish 4/10 Entry $8.68 to $14.07 Now $10.46 −20.51% ▼ −62.10% −57.70% vs SPY
  10. Jun 2, 202623w ago Press Release Bearish 6/10 Entry $8.11 to $13.97 Now $10.46 −28.98% ▼ −72.26% −71.14% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026